Slow-release isradipine in mild to moderate hypertension: hemodynamic and antihypertensive effects. 1991

A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
University of Naples, Italy.

In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler echocardiographic data to investigate the antihypertensive and hemodynamic effects of isradipine 5 mg in the new slow-release oral (SRO) formulation administered once daily for 12 weeks to 10 patients with mild to moderate hypertension. The antihypertensive action of SR isradipine was revealed by the normalized values of casual BP in 60 patients and by the significant reduction of 24-h BP variability as assessed by mean standard variation, coefficient of variation and the percent incidence of abnormal levels of both systolic and diastolic BP during 24 h (p less than .001). The echocardiographic data showed some beneficial hemodynamic effects (improvement of systolic and diastolic indices) without significant variation of left ventricular structure. The drug was well tolerated, with a low incidence of side effects. In conclusion, SR isradipine can be considered a safe and effective first-choice drug for the treatment of mild to moderate hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001795 Blood Pressure Determination Techniques used for measuring BLOOD PRESSURE. Blood Pressure Determinations,Determination, Blood Pressure
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004095 Dihydropyridines Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
February 1991, American journal of hypertension,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
May 1989, The American journal of cardiology,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
October 1988, International journal of clinical pharmacology, therapy, and toxicology,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
March 1993, American journal of hypertension,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
October 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
January 1991, Journal of cardiovascular pharmacology,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
January 1989, Therapie,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
August 2002, Journal of cardiovascular pharmacology,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
January 1992, Journal of cardiovascular pharmacology,
A Celentano, and M Galderisi, and P Tammaro, and G F Mureddu, and M Garofalo, and G de Simone, and O de Divitiis
October 1987, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!